Bendroflumethiazide in pregnancy and breastfeeding


Risk Factor: CM*
Class: Diuretics

Contents of this page:
Fetal Risk Summary
Breast Feeding Summary

Fetal Risk Summary

Bendroflumethiazide is a thiazide diuretic. Animal reproduction studies during the period of organogenesis have not been conducted with this agent.

In a study reported in 1964, 1,011 women received bendroflumethiazide, 5 mg/day, from the 30th week of gestation until delivery in an attempt to prevent preeclampsia and eclampsia (1). No fetal adverse effects were noted.

See Chlorothiazide for other reports of the clinical use of thiazide diuretics in pregnancy and the potential fetal and newborn toxicity of these agents. In general, diuretics are not recommended in the treatment of pregnancy-induced hypertension because of the maternal hypovolemia characteristic of this disease.

[*Risk Factor D if used in pregnancy-induced hypertension.]

Breast Feeding Summary

Bendroflumethiazide has been used to suppress lactation (2). (See Chlorothiazide.)



  1. Cuadros A, Tatum HJ. The prophylactic and therapeutic use of bendroflumethiazide in pregnancy. Am J Obstet Gynecol 1964;89:8917.
  2. Healy M. Suppressing lactation with oral diuretics. Lancet 1961;1:13534.

Please enable JavaScript to view the comments powered by comments powered by Disqus